Quartz·1 min read·medium
FDA advisory panel backed Replimune's twice-rejected melanoma treatment in 10-3 vote
✦AI Summary
An FDA advisory panel has voted 10-3 in favor of Replimune's melanoma treatment, RP1. This recommendation improves the likelihood of approval for the viral immunotherapy ahead of the August 2 decision deadline.
The vote raises the chance the FDA will approve RP1, an engineered viral immunotherapy, ahead of an Aug. 2 decision deadline
healthbusinessscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in